The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro
Open accessAbstract
The sialidase (neuraminidase) inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid (4-guanidino-Neu5Ac2en) has been examined for the ability to inhibit the growth of a wide range of influenza A and B viruses in vitro in comparison with amantadine, rimantadine, and ribavirin. 4-Guanidino-Neu5Ac2en inhibited plaque formation by laboratory-passaged strains of influenza A and B viruses, with 50% inhibitory concentrations ranging from 0.005 to 0.014 microM. A wider range of values (0.02 to 16 microM) was obtained with more recent clinical isolates, but in all cases 4-guanidino-Neu5Ac2en inhibited influenza A and B virus replication at lower concentrations than amantadine, rimantadine, or ribavirin. Inhibition by 4-guanidino-Neu5Ac2en was not obviously affected by the passage history of the viruses or by resistance to amantadine or rimantadine. 4-Guanidino-Neu5Ac2en was a very potent inhibitor of the sialidases of all the influenza viruses examined, with 50% inhibitory concentrations ranging from 0.00064 to 0.0079 microM. No cytotoxicity was observed with 4-guanidino-Neu5Ac2en at up to 10 mM. 4-Guanidino-Neu5Ac2en therefore represents a new potent and selective inhibitor of influenza A and B virus sialidase activity and replication in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
Self-citationStructure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution
Varghese, J. N., Laver, W. G., & Colman, P. M. (1983) · Nature · doi:10.1038/303035a0 · Cited by 891
Potier, M., Mameli, L., Bélisle, M., Dallaire, L., & Melançon, S. B. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90362-2 · Cited by 815
Emergence and Apparent Transmission of Rimantadine-Resistant Influenza A Virus in Families
Hayden, F. G., Belshe, R. B., Clover, R. D., Hay, A. J., Oakes, M. G., & Soo, W. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912213212502 · Cited by 416
Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid
Meindl, P., Bodo, G., Palese, P., Schulman, J., & Tuppy, H. (1974) · Virology · doi:10.1016/0042-6822(74)90080-4 · Cited by 287
Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection
Belshe, R. B., Smith, M. H., Hall, C. B., Betts, R., & Hay, A. J. (1988) · Journal of Virology · doi:10.1128/jvi.62.5.1508-1512.1988 · Cited by 287
Plaque inhibition assay for drug susceptibility testing of influenza viruses
Hayden, F. G., Cote, K. M., & Douglas, R. G. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.17.5.865 · Cited by 278
Coates, J. A., Cammack, N., Jenkinson, H. J., Jowett, A. J., Jowett, M. I., Pearson, B. A., Penn, C. R., Rouse, P. L., Viner, K. C., & Cameron, J. M. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.4.733 · Cited by 240
Self-citationRobertson, J. S., Bootman, J. S., Newman, R., Oxford, J. S., Daniels, R. S., Webster, R. G., & Schild, G. C. (1987) · Virology · doi:10.1016/0042-6822(87)90040-7 · Cited by 218
Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs
Robertson, J. S., Naeve, C. W., Webster, R. G., Bootman, J. S., Newman, R., & Schild, G. C. (1985) · Virology · doi:10.1016/0042-6822(85)90105-9 · Cited by 206
Cited by
Kim, C. U., Lew, W., Williams, M. A., Liu, H., Zhang, L., Swaminathan, S., Bischofberger, N., Chen, M. S., Mendel, D. B., Tai, C. Y., et al. (1997) · Journal of the American Chemical Society · doi:10.1021/ja963036t · Cited by 1,100
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial
Nicholson, K., Aoki, F., Osterhaus, A., Trottier, S., Carewicz, O., Mercier, C., Rode, A., Kinnersley, N., & Ward, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02288-1 · Cited by 785
Hayden, F. G., Osterhaus, A. D. M. E., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., & Wightman, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371302 · Cited by 762
The war against influenza: discovery and development of sialidase inhibitors
von Itzstein, M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2400 · Cited by 702
Computer Aided Drug Design: Success and Limitations
Hassan Baig, M., Ahmad, K., Roy, S., Mohammad Ashraf, J., Adil, M., Haris Siddiqui, M., Khan, S., Amjad Kamal, M., Provazník, I., & Choi, I. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151125000550 · Cited by 424
Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802
He, G., Massarella, J., & Ward, P. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937060-00003 · Cited by 410
Successful Applications of Computer Aided Drug Discovery: Moving Drugs from Concept to the Clinic
Talele, T., Khedkar, S., & Rigby, A. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790232251 · Cited by 407
Matrosovich, M., Matrosovich, T., Carr, J., Roberts, N. A., & Klenk, H.-D. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8418-8425.2003 · Cited by 358
Predicting Influenza Infections during Epidemics with Use of a Clinical Case Definition
Boivin, G., Hardy, I., Tellier, G., & Maziade, J. (2000) · Clinical Infectious Diseases · doi:10.1086/317425 · Cited by 347
Smith, P. W., Sollis, S. L., Howes, P. D., Cherry, P. C., Starkey, I. D., Cobley, K. N., Weston, H., Scicinski, J., Merritt, A., Whittington, A., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970374b · Cited by 342
Self-citationInfluenza virus neuraminidase: Structure, antibodies, and inhibitors
Colman, P. M. (1994) · Protein Science · doi:10.1002/pro.5560031007 · Cited by 333
Zanamivir in the Prevention of Influenza Among Healthy Adults: A Randomized Controlled Trial
Monto, A. S., Robinson, D. P., Herlocher, M. L., Hinson, Jr., Elliott, M. J., & Crisp, A. (1999) · JAMA · doi:10.1001/jama.282.1.31 · Cited by 321
Resistance of influenza viruses to neuraminidase inhibitors — a review
MCKIMMBRESCHKIN, J. (2000) · Antiviral Research · doi:10.1016/s0166-3542(00)00103-0 · Cited by 320
Selection of Influenza Virus Mutants in Experimentally Infected Volunteers Treated with Oseltamivir
Gubareva, L. V., Kaiser, L., Matrosovich, M. N., Soo‐Hoo, Y., & Hayden, F. G. (2001) · The Journal of Infectious Diseases · doi:10.1086/318537 · Cited by 318
(1998) · The Lancet · doi:10.1016/s0140-6736(98)10190-3 · Cited by 351
Microbial recognition of target-cell glycoconjugates
Karlsson, K.-A. (1995) · Current Opinion in Structural Biology · doi:10.1016/0959-440x(95)80054-9 · Cited by 310
Safety and Efficacy of the Neuraminidase Inhibitor GG167 in Experimental Human Influenza
Hayden, F. G. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530280047035 · Cited by 291
Monto, A. S., Fleming, D. M., Henry, D., de Groot, R., Makela, M., Klein, T., Elliott, M., Keene, O. N., & Man, C. Y. (1999) · The Journal of Infectious Diseases · doi:10.1086/314904 · Cited by 275
Mendel, D. B., Tai, C. Y., Escarpe, P. A., Li, W., Sidwell, R. W., Huffman, J. H., Sweet, C., Jakeman, K. J., Merson, J., Lacy, S. A., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.640 · Cited by 255
Metadata
- Authors
- Woods, J. M., Bethell, R. C., Coates, J. A., Healy, N., Hiscox, S. A., Pearson, B. A., Ryan, D. M., Ticehurst, J., Tilling, J., & Walcott, S. M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1993-07
- Volume
- 37
- Issue
- 7
- Pages
- 1473-1479
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2115959170
- Cited by
- 312
- References
- 21
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.